Natera at the 2025 ESMO Annual Meeting
Natera is set to present 14 studies at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany, reinforcing Natera’s position as a leader in molecular residual disease (MRD) testing across multiple cancer types:
- Highlighted abstracts include the IMvigor011 Oral Presentation at the Presidential Symposium
- Five oral presentations underscore Natera’s leadership in bladder cancer and the expanding role of ctDNA across other solid tumors, reinforcing Natera’s position as a leader in molecular residual disease (MRD) testing across multiple cancer types
Learn about our expanding body of data in solid tumor malignancies
Friday, October 17 Click to collapse
3068O – Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Speakers: Matthew D. Galsky (New York, United States of America)Session: Proffered Paper session 1: GU tumours, renal & urothelial
Room: Dortmund Auditorium - Hall 7.1a
Date: Fri, 17.10.2025 | Time: 14:00 - 15:30 | Lecture: 14:50 - 15:00
LBA112 – Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results
Speakers: Andrea Necchi (Milan, Italy)Session: Mini Oral session 1: GU tumours, renal & urothelial
Room: Karlsruhe Auditorium - Hall 5.2
Date: Fri, 17.10.2025 | Time: 16:00 - 17:30 | Lecture: 16:40 - 16:45
Saturday, October 18 Click to expand
Sunday, October 19 Click to expand
Monday, October 20 Click to expand
To learn more about this and other important data as well as how Signatera™ may be used to help answer key clinical questions within your practice
Patient Testimonial
Listen to muscle invasive bladder patient Brent tell his story on how his care team chose to monitor him with Signatera™ throughout his cancer treatment and during surveillance to help better inform therapy decisions.
Not all MRD tests are created equal
Signatera™ is the most comprehensive MRD test available. Review our peer-reviewed publications here.